CClinicalTrials.gg
CompletedNCT02298452Updated May 3, 2016

Performance of a Hearing Aid Platform Including Different Styles of Hearing Aids

An interventional study of Hearing aid. in Hearing Loss, Bilateral or Unilateral, sponsored by Phonak AG, Switzerland. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2016-05-03.

Sponsored by Phonak AG, Switzerland · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
253
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The reason for this study is to evaluate a new hearing aid product generation replacing the one on the market. The goal is to evaluate the audiological performance, usability as well as features and functions.

Read the detailed description

This is a controlled, single blinded comparative study which is conducted monocentric at Phonak Headquarters in Staefa. The focus is to compare a new hearing aid product generation with the one on the market as well as with competitor devices regarding the audiological performance, usability as well as features and functions with the aid of 382 mild to profound hearing impaired subjects (18-90 yrs). The subjects, all of them native (Swiss) German speakers, individually conduct a number of laboratory standard tests and home trials (questionnaires) during nine weeks including weekly appointments of 2 hours.

02

Conditions studied

  • Hearing Loss, Bilateral or Unilateral
03

In context

Hearing Loss

1,092 studies on the registry are indexed under Hearing Loss; 235 are open to participants now.

This study's enrollment of 253 is above the median of 40 across 764 interventional studies indexed under Hearing Loss.

Browse Hearing Loss studies →

Lead sponsor

Phonak AG, Switzerland is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • all kinds of hearing loss (sensorineural, conductive, combined)
  • all kinds of hearing loss (flat, sloping) which are in the fitting range of the hearing aids
  • mother tongue (swiss) german

Exclusion criteria

Exclusion Criteria:

Subjects

  • with a reduced mobility unable to attend weekly study appointments
  • without access to a number of different hearing situations
  • with strongly reduced ability to describe auditory impressions and the usage of the hearing aids
  • which are uncooperative so that it is not possible to record a valid pure tone audiogram
  • with a strongly reduced dexterity
  • with psychological problems
  • central hearing disorders
05

Study design

Phase
Not applicable
Allocation
Not applicable
Intervention model
Single group
Masking
Single (Participant)
Enrollment
253 participants (actual)

Study arms

  • Other
    Hearing aid

    172 subjects with a mild hearing loss. 140 subjects with a moderate hearing loss. 70 subjects with a severe/ profound hearing loss.

    Device: Hearing aid.

Interventions

  • DeviceHearing aid.

    The hearing aid will be fitted to the individual hearing loss of the subject.

06

What researchers measure

Primary outcomes

  1. Difference of speech intelligibility between devices based on Quest platform and Venture platform for different hearing aid styles

    For the objective measurements in laboratory situation, both a standard German speech sentence test in noise (SRT in dB) and a standard German monosyllable word test in quiet (speech discrimination in percent) are used to compare the speech intelligibility for both platforms. The results of the Venture platform of both tests should be at least the same or better than with the Quest platform.

    Time frame: 3 years

Secondary outcomes

  1. Subjective ratings of speech intelligibility during home trials

    For the subjective rating of speech intelligibility, questionnaires are used to compare the current platform Quest with the new platform Venture. The subjective impressions are rated by rating scales (e.g. Speech intelligibility in quiet: everything - most - half - little - nothing).

    Time frame: 3 years

  2. Subjective ratings of sound quality during home trials

    For the subjective rating of sound quality, questionnaires are used to compare the current platform Quest with the new platform Venture. The subjective impressions are rated by rating scales (e.g. Sound quality for speech in quiet: good - dull - sharp - thin - echo - scratchy - unclear - noisy).

    Time frame: 3 years

  3. Subjective ratings of usability during home trials

    For the subjective rating of usability, questionnaires are used to compare the current platform Quest with the new platform Venture . The subjective impressions are rated by rating scales (e.g. Rating of the opening and closing of the battery door: very easy - easy - neither - difficult - very difficult).

    Time frame: 3 years

07

Study locations

1 site
  • Phonak AG
    Stäfa, Zürich 8712, Switzerland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02298452
Lead sponsor
Phonak AG, Switzerland
Responsible party
Sponsor
First posted
Nov 24, 2014
Start date
May 2013
Primary completion
Aug 2015
Completion
Sep 2015
Last update
May 3, 2016

Study contacts

Simone Ebbing, B. Sc.
principal investigator · Phonak AG

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion